Intensive Models of HCV Care for Injection Drug Users

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-01

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival. However, IDUs have had poor access to HCV care and their success in HCV treatment has been limited. With direct-acting antiviral agents, HCV treatment delivered within large clinical trials leads to SVR or cure in over 70% of genotype-1 infected patients, compared to 45% with previous therapies. However, SVR rates are as low as 14% in real-world settings. The majority of patients who fail to achieve SVR will develop drug resistance, but the optimal adherence level to minimize resistance is unknown. If HCV treatment continues to be delivered within current models of care, most IDUs will not only fail treatment and develop resistance, but may transmit resistant viruses to others. We have previously developed a multidisciplinary model of HCV care which integrates on-site primary care, substance abuse treatment, psychiatric care, and HCV-related care within opiate agonist treatment clinics. To maximize treatment outcomes, we piloted two models of intensive HCV-related care: directly observed therapy (DOT), and concurrent group therapy (CGT). In our DOT model, pegylated interferon is administered once weekly, if applicable, and one daily dose of oral medication is administered at the methadone window. In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides powerful social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections, if applicable. It is unknown whether either model is better or more cost-effective than standard on-site care.

PREVAIL 1: In the proposed study, 150 IDUs with chronic HCV (genotype 1) will be recruited from methadone clinics and randomized to one of three models of care: DOT; concurrent group treatment; or standard on-site care. Our specific aims are: 1) To determine whether either of two intensive on-site HCV treatment models (DOT or concurrent group treatment) is more efficacious than standard on-site treatment for enhancing adherence and SVR, and decreasing drug resistance; (2) To determine the incidence and factors associated with the development of drug resistance in IDUs; (3) To perform cost and cost-effectiveness analyses of each model; (4) To examine the impact of HIV coinfection on adherence and virologic outcomes among HCV-infected IDUs.

PREVAIL 2: In the proposed study, 60 IDUs with chronic HCV (genotypes 1 2, 3 and 4) will be recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will be offered the choice of model of care (either standard on-site, DOT, or concurrent group treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of opiate agonist treatment patients initiating treatment with sofosbuvir-based regimens and (2) to determine adherence rates over time in drug users (genotype 3 and genotype 1 / IFN-ineligible) initiating a 24 week IFN-free regimen.

PREVAIL 3: In the proposed study, 60 IDUs with chronic HCV (genotype 1 and 4) will be recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will be offered the choice of model of care (either standard on-site, DOT, or concurrent group treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of opiate agonist treatment patients initiating treatment with oral DAA combination of sofosbuvir and simeprevir or fixed dose of sofosbuvir and ledipasvir and (2) to determine adherence rates over time in drug users.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improving Hepatitis C Treatment in Injection Drug Users

NCT00148031

Hepatitis C Liver Diseases Drug Abuse +1 more

COMPLETED PHASE4

Patient-Centered Models of HCV Care for People Who Inject Drugs

NCT02824640

Hepatitis C Medication Adherence

COMPLETED NA

A Trial to Reduce Hepatitis C Among Injection Drug Users - 1

NCT00218192

HCV Negative Status HCV Risk Behavior

COMPLETED PHASE3

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

NCT00194480

Substance-Related Disorders Hepatitis

COMPLETED PHASE4

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750

Hepatitis C

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PREVAIL 1: In the proposed study, 150 IDUs with chronic HCV (genotype 1) will be recruited from methadone clinics and randomized to one of three models of care: DOT; concurrent group treatment; or standard on-site care. Our specific aims are: 1) To determine whether either of two intensive on-site HCV treatment models (DOT or concurrent group treatment) is more efficacious than standard on-site treatment for enhancing adherence and SVR, and decreasing drug resistance; (2) To determine the incidence and factors associated with the development of drug resistance in IDUs; (3) To perform cost and cost-effectiveness analyses of each model; (4) To examine the impact of HIV coinfection on adherence and virologic outcomes among HCV-infected IDUs.

PREVAIL 2: In the proposed study, 60 IDUs with chronic HCV (genotypes 1 2, 3 and 4) will be recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will be offered the choice of model of care (either standard on-site, DOT, or concurrent group treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of opiate agonist treatment patients initiating treatment with sofosbuvir-based regimens and (2) to determine adherence rates over time in drug users (genotype 3 and genotype 1 / IFN-ineligible) initiating a 24 week IFN-free regimen.

PREVAIL 3: In the proposed study, 60 IDUs with chronic HCV (genotype 1 and 4) will be recruited from opiate agonist treatment programs and started on HCV treatment. Subjects will be offered the choice of model of care (either standard on-site, DOT, or concurrent group treatment). Our specific aims are: (1) to determine rates of adherence and SVR in a cohort of opiate agonist treatment patients initiating treatment with oral DAA combination of sofosbuvir and simeprevir or fixed dose of sofosbuvir and ledipasvir and (2) to determine adherence rates over time in drug users.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Medication Adherence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Modified Directly Observed Therapy (mDOT)

In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.

Group Type EXPERIMENTAL

Intensive Models (mDOT and CGT) of HCV Care

Intervention Type OTHER

Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.

Concurrent Group Treatment (CGT)

In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.

Group Type EXPERIMENTAL

Intensive Models (mDOT and CGT) of HCV Care

Intervention Type OTHER

Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.

Treatment as Usual

In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.

Group Type ACTIVE_COMPARATOR

Intensive Models (mDOT and CGT) of HCV Care

Intervention Type OTHER

Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intensive Models (mDOT and CGT) of HCV Care

Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PREVAIL 1:

* HCV-infected, Genotype-1
* Treatment naïve or treatment experienced patients
* Willing to receive HCV treatment on-site
* Initiating treatment with direct-acting antiviral agents (DAA) with or without ribavirin +/- pegylated interferon alfa-2a
* Receiving methadone or buprenorphine in clinic at least one time per week
* Age 18 or older
* Able to provide informed consent
* Psychiatrically stable
* English or Spanish speaking
* Currently enrolled in a methadone or buprenorphine treatment program in the designated clinics in the Bronx (Melrose, Port Morris, Waters Place)

* HCV-infected, Genotype-1, , 2, 3, or 4
* Willing to receive HCV treatment on-site at an opiate agonist treatment program.
* Initiating treatment with sofosbuvir and ribavirin +/- pegylated interferon alfa-2a
* Age 18 or older
* Able to provide informed consent
* English or Spanish speaking
* Currently a patient in one of the designated clinics in the Bronx (Melrose, Port Morris, Waters Place)

* HCV-infected, Genotype-1 or 4
* Willing to receive HCV treatment on-site at an opiate agonist treatment program.
* Initiating treatment with oral DAA combination of sofosbuvir and simeprevir or fixed dose of sofosbuvir and ledipasvir.
* Age 18 or older
* Able to provide informed consent
* English or Spanish speaking
* Currently a patient in one of the designated clinics in the Bronx (Melrose, Port Morris, Waters Place)

* HCV-infected, Genotype-1
* Treatment naïve or treatment experienced patients
* Willing to receive HCV treatment on-site
* Initiating treatment with direct-acting antiviral agents (DAA) with or without ribavirin +/- pegylated interferon alfa-2a
* Age 18 or older
* Able to provide informed consent
* Psychiatrically stable
* English or Spanish speaking

Exclusion Criteria

* Known hypersensitivity (allergy) to interferon, ribavirin or DAA
* Psychiatrically unstable
* Pregnant or breast-feeding

PREVAIL 2:

* Known hypersensitivity (allergy) to interferon, ribavirin or sofosbuvir
* Pregnant or breast-feeding

PREVAIL 3:

* Known hypersensitivity (allergy) to sofosbuvir, simprevir or ledipasvir.
* Pregnant or breast-feeding

PREVAIL 4

* Known hypersensitivity (allergy) to interferon, ribavirin or DAA
* Psychiatrically unstable
* Pregnant or breast-feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No